QSAM Biosciences
View On Demand

CycloSam has been granted Orphan Drug and Rare Pediatric Disease Designations by the FDA

About the Event

QSAM Biosciences (OTCQB: QSAM) is a clinical-stage radiopharmaceutical company that is developing a next generation treatment for metastatic bone cancer and primary bone cancers such as osteosarcoma and Ewings Sarcoma. The FDA has cleared an IND for their lead asset, CycloSam®, to address the $20B bone mets market and a phase 1 trial is expected to be completed later this year.

CycloSam has also been granted Orphan Drug and Rare Pediatric Disease designations by the FDA for osteosarcoma. QSAM expects to hit several important milestones and value inflection points in the next 24-months, and the company will look to apply this platform technology to other large indications in the coming years.

Join this webinar to hear QSAM CEO, Douglas Baum and
Justin Walsh PhD, Health Analyst for Jones Trading discuss their derisked treatment for the $20B bone cancer market.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.